Protection by a Recombinant DNA Vaccine Against Hepatitis B, Preliminary Report

  • C. Goilav
  • H. Prinsen
  • A. Safary
  • F. E. André
  • P. Piot

Abstract

Between April 1985 and March 1986, 314 gay men, aged 18–64 years, all negative for hepatitis B (HBV) infection, were enrolled into a clinical study to evaluate the immune response and to estimate the protection given by a recombinant DNA vaccine against HBV (Engerix-B, SmithKline Biologicals, Rixen-sart, Belgium) in a high-risk group. At this time, the vaccine schedule was three doses at months 0, 1 and 6 intramuscularly (deltoid region). Boosters were given if the serum level of anti-HBs was below 100 IU/liter in the follow-up period. Control samples were taken at months − 1,1, 3,6, 7,12 and 24. Symptom sheets were collected after each injection. Two doses of vaccine were tested (20 or 40 µg). In the groups available for analysis the seroconversion rate for anti-HBs at month 7 was 98% in both dose ranges and the geometric mean titers (GMTs) of anti-HBs were 1027 (n= 131) and 2363 IU/liter (n = 66) respectively. The seroconversion rates and persistence are shown in Table I. Some candidates had a spontaneous rise of their anti-HBs levels (with more

Keywords

Fatigue Hepatitis Protec 

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • C. Goilav
  • H. Prinsen
  • A. Safary
  • F. E. André
  • P. Piot

There are no affiliations available

Personalised recommendations